Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Zanidatamab (Primary) ; Capecitabine; Docetaxel; Oxaliplatin
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene

Most Recent Events

  • 25 Nov 2024 Status changed from active, no longer recruiting to completed.
  • 24 Oct 2023 Updated results of cohort 2 (as of 22 Nov 2022, n= 33) presented at the 48th European Society for Medical Oncology Congress.
  • 16 Oct 2023 According to a Jazz Pharmaceuticals plc media release, clinical data featuring progression-free survival (PFS) and duration of response (DoR) from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place in Madrid, Spain, from October 20-24, 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top